Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Inclusion Criteria

• Participants who had advanced unresectable and/or metastatic cervical cancer (squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma) with disease progression during or after the prior platinum-containing chemotherapy:
• The prior platinum-containing chemotherapy may be a systemic treatment for advanced unresectable, recurrent, persistent or metastatic disease or treatment in the adjuvant or neo-adjuvant setting with disease progression or recurrence within 6 months of completion of platinum-containing chemotherapy
• Participants who previously only received platinum as a radiosensitizer are not eligible
• Participants must be naïve to checkpoint inhibitors
• Participants who had measurable disease
• Participants who provide a tumor tissue sample, either from archival tissue or newly obtained core or excisional biopsy. If the participant received local therapy (For example: radiation therapy or chemoradiotherapy) after the archival tissue was taken, a new biopsy was required
• Participants who had Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1
• Life expectancy greater than or equals to (>=) 12 weeks as judged by the Investigator
• Adequate hematological, hepatic and renal function as defined in the protocol
• Participants with known Human Immunodeficiency Virus (HIV) infections were in general eligible if the following criteria are met:
• Clinically indicated participants must be stable on antiretroviral therapy (ART) for at least 4 weeks and agree to adhere to ART
• had no evidence of documented multi-drug resistance that would prevent effective ART
• had an HIV viral load of < 400 copies per milliliter (/mL) at Screening
• had CD4+ T-cell (CD4+) counts >= 350 cells/microliter
• For participants with a history of an Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the last 12 months, participants may be eligible only after consultation and agreement with the study Medical Monitor
• If prophylactic antimicrobial drugs were indicated, participants would still be considered eligible upon agreement with the study Medical Monitor
• Participants with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections were in general eligible if the following criteria are met:
• HBV viral load below the limit of quantification. If medically indicated, participants infected with HBV must be treated and on a stable dose of antivirals at study entry and with planned monitoring and management according to appropriate labeling guidance
• Participants with a history of HCV infection should have completed curative antiviral treatment and require HCV viral load below the limit of quantification
• Participants on concurrent HCV treatment should have HCV below the limit of quantification
• Other protocol defined inclusion criteria could apply

Exclusion Criteria

• Participants with active central nervous system (CNS) metastases causing clinical symptoms or require therapeutic intervention are excluded. Participants with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 4 weeks, and are not using steroids for at least 7 days prior to the start of study treatment
• Participants with interstitial lung disease or has had a history of pneumonitis that has required oral or intravenous (IV) steroids
• Participants with significant acute or chronic infections
• Participants with active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
• Participants with clinically significant cardiovascular/cerebrovascular disease including: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, or serious cardiac arrhythmia
• Other protocol defined exclusion criteria could apply